Boston Scientific (BSX) 'Surprises' ACC with WATCHMAN Presentation Plans
Tweet Send to a FriendGet Alerts BSX Hot Sheet
Trade BSX Now!
Boston Scientific (NYSE: BSX) said on Monday that is planned to present "acute procedural safety results of the PREVAIL clinical trial that evaluates the WATCHMAN left atrial appendage closure device in patients with nonvalvular atrial fibrillation versus long-term warfarin therapy" at the 62nd Annual Scientific Session of the American College of Cardiology this weekend, a more limited release of data than was expected.
According to reports out Tuesday, the data is currently under review ahead of the presentation this weekend. One spokesperson for the ACoC said, "The release yesterday surprised us. We are investigating with them how much they will present."
WATCHMAN is used to seal off a reservoir in the upper chamber of the heart, where blood could form pools, potentially leading to clots. The study is being conducted to see whether WATCHMAN would be able to prevent strokes.
Shares of Boston Scientific are down 0.5 percent on the session.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
According to reports out Tuesday, the data is currently under review ahead of the presentation this weekend. One spokesperson for the ACoC said, "The release yesterday surprised us. We are investigating with them how much they will present."
WATCHMAN is used to seal off a reservoir in the upper chamber of the heart, where blood could form pools, potentially leading to clots. The study is being conducted to see whether WATCHMAN would be able to prevent strokes.
Shares of Boston Scientific are down 0.5 percent on the session.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Amarin's (AMRN) Vascepa Not in FDA Orange Book for April
- Boston Scientific Presents Clinical Data at Digestive Disease Week®
- EnteroMedics (ETRM) Higher; Completes VBLOC Therapy Pre-PMA Meeting With FDA
Create E-mail Alert Related Categories
FDA, Insiders' Blog
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
